Search

Your search keyword '"Borlongan C.V."' showing total 36 results
Start Over Author "Borlongan C.V."
36 results on '"Borlongan C.V."'

3. List of Contributors

Author

Abbatemarco, J.A., primary, Adams, R.J., additional, Adkins, D.L., additional, Akamatsu, Y., additional, Akyol, O., additional, Alexandrov, A.V., additional, Alim, I., additional, Alkhachroum, A.M., additional, Amin-Hanjani, S., additional, Andjelkovic, A.V., additional, Anrather, J., additional, Applegate, R., additional, Arai, K., additional, Ayata, C., additional, Aziz-Sultan, M.A., additional, Ballesteros, I., additional, Bar, B., additional, Barone, F.C., additional, Barrow, D.L., additional, Başkaya, M.K., additional, Bateman, K., additional, Bazan, N.G., additional, Beecher, J.S., additional, Beer-Furlan, A., additional, Belayev, L., additional, Bhattacharya, P., additional, Bhole, R., additional, Biller, J., additional, Biousse, V., additional, Borlongan, C.V., additional, Bouts, M.J.R.J., additional, Brey, R.L., additional, Bronstein, R., additional, Bryer, A., additional, Bulsara, K.R., additional, Can, A., additional, Canhão, P., additional, Caplan, L.R., additional, Carmichael, S.T., additional, Carrau, R., additional, Castaldo, J., additional, Catanese, L., additional, Chabriat, H., additional, Chaturvedi, S., additional, Chaudhary, N., additional, Chen, Jieli, additional, Chen, S., additional, Chen, Jun, additional, Choi, D.W., additional, Choi, B., additional, Chopp, M., additional, Chung, D.Y., additional, Chung, C.-P., additional, Cipolla, M.J., additional, Colbourne, F., additional, Colburn, Q., additional, Cord, B.J., additional, Coull, B.M., additional, Cuartero, M.I., additional, Cummings, J.L., additional, Dafer, R.M., additional, Dalkara, T., additional, Daou, B., additional, Dave, K.R., additional, Davis, T.P., additional, De Georgia, M., additional, De Silva, T.M., additional, Dharap, A., additional, Di Tullio, M.R., additional, Dietrich, W.D., additional, Dijkhuizen, R.M., additional, Dobkin, B.H., additional, Du, R., additional, Ducruet, A.F., additional, Duncan, K.R., additional, Edvinsson, L., additional, Edwards, M.J., additional, Egemen, E., additional, El-Hunjul, M., additional, Emanuele, M., additional, Emanuele, N., additional, Erdman, M.K., additional, Ergul, A., additional, Fagan, S.C., additional, Faraci, F.M., additional, Federau, C., additional, Ferro, J.M., additional, Fisher, M., additional, Flemming, K.D., additional, Foerch, C., additional, Freitas, R.S., additional, Friedlander, R.M., additional, Gaberel, T., additional, Gakuba, C., additional, Giffard, R.G., additional, Goldberg, M.P., additional, González, R.G., additional, Gopinath, S., additional, Gorelick, P.B., additional, Goshgarian, C., additional, Greenberg, D.A., additional, Griessenauer, C.J., additional, Groshans, K.A., additional, Gupta, R., additional, Hachem, R.A., additional, Hage, Z.A., additional, Hall, E.D., additional, Hamel, E., additional, Hao, Q., additional, Haqqani, A.S., additional, Hariman, R., additional, Hasan, D., additional, Haussen, D.C., additional, He, L., additional, Heiferman, D.M., additional, Herndon, J.M., additional, Ho, W.M., additional, Hoffmann, S., additional, Howard, B.M., additional, Hu, B.R., additional, Huber, J.D., additional, Huisa, B., additional, Hurn, P.D., additional, Iliff, J.J., additional, Jabbour, P., additional, Jamshidi, A.O., additional, Jankowitz, B., additional, Jickling, G.C., additional, Johansen, M., additional, Jovin, T.G., additional, Karuppagounder, S.S., additional, Kasper, E.M., additional, Keep, R.F., additional, Kim, H.-H., additional, Kim, D.E., additional, Kim, J.S., additional, Kim, J.Y., additional, Klahr, A.C., additional, Koch, M.J., additional, Kole, M., additional, Koleilat, S.M., additional, Kozan, A., additional, Kuroda, S., additional, Lamy, C., additional, Lanzino, G., additional, Larsen, A.G., additional, Laviv, Y., additional, Lawton, M.T., additional, Leary, M.C., additional, Leira, E.C., additional, Li, L., additional, Li, Q., additional, Liebeskind, D.S., additional, Lin, L., additional, Lioutas, V.A., additional, Lippert, T., additional, Liu, R., additional, Liu, J., additional, Liu, C.L., additional, Lizasoain, I., additional, Lo, E.H., additional, Loftus, C.M., additional, Logsdon, A.F., additional, Lucke-Wold, B.P., additional, Madhavan, S., additional, Madhugiri, V., additional, Malhotra, K., additional, Manning, W.J., additional, Marcell, S.J., additional, Mas, J.-L., additional, Masamoto, K., additional, Matute, C., additional, McCullough, L.D., additional, McDowell, M.M., additional, Mehdiratta, M., additional, Mehta, D., additional, Meisel, A., additional, Messegee, J., additional, Miller, B., additional, Mirza, S., additional, Modak, J.M., additional, Moro, M.A., additional, Nagel, M.A., additional, Namura, S., additional, Nedergaard, M., additional, Newell, D.W., additional, Newman, N.J., additional, Ng, K.L., additional, Nguyen, D., additional, Nguyen, H., additional, Nielsen, G., additional, Nishijima, Y., additional, Nishimura, N., additional, Nogueira, R.G., additional, Ogilvy, C.S., additional, Orbach, D.B., additional, Ostendorf, A.P., additional, Otto, B., additional, Ozpinar, A., additional, Panczykowski, D.M., additional, Patel, A.B., additional, Perez, Y., additional, Perez-Pinzon, M.A., additional, Potey, C., additional, Pradillo, J.M., additional, Prevedello, D.M., additional, Rajamani, K., additional, Rangel-Castilla, L., additional, Rao, N.M., additional, Ratan, R.R., additional, Raval, A.P., additional, Reddy, G.D., additional, Reis, C., additional, Roach, E.S., additional, Ronaldson, P.T., additional, Rosen, C.L., additional, Rosenberg, G.A., additional, Rutledge, W.C., additional, Sabzwari, R., additional, Salzano, G., additional, Santucci, P.A., additional, Saver, J.L., additional, Schallert, T., additional, Schermerhorn, M.L., additional, Schneck, M.J., additional, See, A.P., additional, Shakir, H.J., additional, Sharp, F.R., additional, Shuja, F., additional, Siddiqui, A.H., additional, Silva, M.A., additional, Singhal, A.B., additional, Sivakumar, K., additional, Slade, D.H., additional, Smith, E.R., additional, Sohrabji, F., additional, Solaroglu, I., additional, Sriraman, S.K., additional, Stamova, B., additional, Stanimirovic, D.B., additional, Stapleton, C.J., additional, Stary, C.M., additional, Steinberg, G.K., additional, Stephen, C., additional, Stetler, R.A., additional, Stone, J., additional, Sumbria, R., additional, Sweis, R., additional, Tahir, R., additional, Tarawneh, R., additional, Tarsia, J., additional, Tehrani, R., additional, Teo, M.K., additional, Testai, F.D., additional, Thrane, A.S., additional, Tobin, M.K., additional, Tome, M.E., additional, Topcuoglu, M.A., additional, Topel, C.H., additional, Torchilin, V., additional, Traystman, R.J., additional, Tsirka, S.E., additional, Turan, Y., additional, Tymianski, M., additional, van Leyen, K., additional, Varade, P., additional, Veluz, J.S., additional, Vemuganti, R., additional, Venkat, P., additional, Vexler, Z.S., additional, Vial, C.M., additional, Vinters, H.V., additional, Vosko, M.R., additional, Waeber, C., additional, Walcott, B.P., additional, Wang, J., additional, Wang, X., additional, Wang, Y.T., additional, Wei, Z.Z., additional, Wei, L., additional, Welch, B.G., additional, Winn, H.R., additional, Wintermark, M., additional, Wityk, R.J., additional, Wu, O., additional, Wu, K.C., additional, Xi, G., additional, Yacoub, H.A., additional, Yakhkind, A., additional, Yamamoto, Y., additional, Yang, S.-H., additional, Yenari, M., additional, Yigitkanli, K., additional, Yonas, H., additional, Yu, Z., additional, Zettervall, S.L., additional, Zhang, J., additional, Zhang, W., additional, and Zhao, H., additional

Published
2017
Full Text
View/download PDF

30. Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications

Author

E. Russo, M. Caprnda, P. Kruzliak, P. G. Conaldi, C. V. Borlongan, G. La Rocca, Russo E., Caprnda M., Kruzliak P., Conaldi P.G., Borlongan C.V., and La Rocca G.

Subjects
Settore BIO/17 - Istologia, Review Article, Cell Biology, mesenchymal stromal cells, stem cells, cartilage, regenerative medicien, tissue engineering, immune modulation, Molecular Biology, Internal medicine, RC31-1245
Abstract

Chondropathies are increasing worldwide, but effective treatments are currently lacking. Mesenchymal stromal cell (MSCs) transplantation represents a promising approach to counteract the degenerative and inflammatory environment characterizing those pathologies, such as osteoarthritis (OA) and rheumatoid arthritis (RA). Umbilical cord- (UC-) MSCs gained increasing interest due to their multilineage differentiation potential, immunomodulatory, and anti-inflammatory properties as well as higher proliferation rates, abundant supply along with no risks for the donor compared to adult MSCs. In addition, UC-MSCs are physiologically adapted to survive in an ischemic and nutrient-poor environment as well as to produce an extracellular matrix (ECM) similar to that of the cartilage. All these characteristics make UC-MSCs a pivotal source for a stem cell-based treatment of chondropathies. In this review, the regenerative potential of UC-MSCs for the treatment of cartilage diseases will be discussed focusing on in vitro, in vivo, and clinical studies.

Published
2022

33. Central and Peripheral Secondary Cell Death Processes after Transient Global Ischemia in Nonhuman Primate Cerebellum and Heart

Author

Yuji Kaneko, Eleonora Russo, Trenton Lippert, Roger Lin, M. Grant Liska, Jea-Young Lee, Hung Nguyen, Cesar V. Borlongan, Lee J.-Y., Lin Roger, Nguyen Hung, Russo Eleonora, Liska M.G., Lippert T., Kaneko Y., and Borlongan C.V.

Subjects
Cell death, Inflammation, Pathology, medicine.medical_specialty, Programmed cell death, Cerebellum, business.industry, Purkinje cell, Neurodegeneration, Ischemia, Stereology, medicine.disease, Secondary injury, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Apoptosis, 030220 oncology & carcinogenesis, Medicine, medicine.symptom, business, 030217 neurology & neurosurgery, Immunostaining
Abstract

Cerebral ischemia and its pathological sequelae are responsible for severe neurological deficits generally attributed to the neural death within the infarcted tissue and adjacent regions. Distal brain regions, and even peripheral organs, may be subject to more subtle consequences of the primary ischemic event which can initiate parallel disease processes and promote comorbid symptomology. In order to characterize the susceptibility of cerebellar brain regions and the heart to transient global ischemia (TGI) in nonhuman primates (NHP), brain and heart tissues were harvested 6 months post-TGI injury. Immunostaining analysis with unbiased stereology revealed significant cell death in lobule III and IX of the TGI cerebellum when compared to sham cerebellum, coinciding with an increase in inflammatory and apoptotic markers. Cardiac tissue analysis showed similar increases in inflammatory and apoptotic cells within TGI hearts. A progressive inflammatory response and cell death within the cerebellum and heart of chronic TGI NHPs indicate secondary injury processes manifesting both centrally and peripherally. This understanding of distal disease processes of cerebral ischemia underscores the importance of the chronic aberrant inflammatory response and emphasizes the needs for therapeutic options tailored to target these pathways. Here, we discuss the protocols for characterizing the histopathological effects of transient global ischemia in nonhuman primate cerebellum and heart, with an emphasis on the inflammatory and apoptotic cell death processes.

Published
2019
Full Text
View/download PDF

34. An update on intracerebral stem cell grafts

Author

Eleonora Russo, M. Grant Liska, Roger Lin, Harry R. van Loveren, Xunming Ji, Cesario V. Borlongan, Elliot G. Neal, Melissa Gonzalez, Trenton Lippert, Kaya Xu, Fernando L. Vale, Neal E.G., Liska M.G., Lippert T., Lin Roger, Gonzalez Melissa, Russo Eleonora, Xu K., Ji X., Vale F.L., Van Loveren H., and Borlongan C.V.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Parkinson's disease, Traumatic brain injury, medicine.medical_treatment, multi-system atrophy, Neuroprotection, 03 medical and health sciences, Graft vs Host Reaction, 0302 clinical medicine, Huntington's disease, Central Nervous System Diseases, Risk Factors, Internal medicine, Medicine, Animals, Humans, Pharmacology (medical), amyotrophic lateral sclerosi, Amyotrophic lateral sclerosis, Stem cell, business.industry, General Neuroscience, Multiple sclerosis, traumatic brain injury, Stem-cell therapy, medicine.disease, stroke, 030104 developmental biology, Blood-Brain Barrier, multiple sclerosi, Parkinson’s disease, neuroprotection, Neurology (clinical), business, 030217 neurology & neurosurgery, Huntington’s disease, Stem Cell Transplantation
Abstract

Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for clinically feasible stem cell-based treatments. Expert commentary: Intracerebral administration, compared to peripheral delivery, is more invasive and carries the risk of open brain surgery. However, direct cell implantation bypasses the blood–brain barrier and reduces the first-pass effect, effectively increasing the therapeutic cell deposition at its intended site of action. These benefits must be weighed with the risk of graft-versus-host immune response. Rigorous clinical trials are underway to assess the safety and efficacy of intracerebral transplants, and if successful will lead to widely available stem cell therapies for neurologic diseases in the coming years.

Published
2018

35. Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS)

Author

Cv V. Borlongan, Sa A. Scherjon, Francesco Alviano, C. Götherström, Susanne Wolbank, Ag G. Betz, Al L. Mellor, Ml L. Weiss, Ornella Parolini, Dw W. Bianchi, Ursula Manuelpillai, Kj J. Wood, Peter Ponsaerts, Racheli Ofir, Parolini O., Alviano F., Betz A.G., Bianchi D.W., Gotherstrom C., Manuelpillai U., Mellor A.L., Ofir R., Ponsaerts P., Scherjon S.A., Weiss M.L., Wolbank S., Wood K.J., and Borlongan C.V.

Subjects
Placenta, Library science, Fetomaternal tolerance, Article, Term placenta, Immunomodulation, Female, Fetal Stem Cells, Fetus, Humans, Pregnancy, Cell transplantation, Adult stem cell, Settore BIO/13 - BIOLOGIA APPLICATA, Medicine, Scientific activity, Inflammation, business.industry, Lung fibrosis, Champion, Obstetrics and Gynecology, Placental cell, Transplantation, Reproductive Medicine, embryonic structures, Immunology, Human medicine, Stem cell, business, Developmental Biology
Abstract

The International Placenta Stem Cell Society (IPLASS) was founded in June 2010. Its goal is to serve as a network for advancing research and clinical applications of stem/progenitor cells isolated from human term placental tissues, including the amnio-chorionic fetal membranes and Wharton’s jelly. The commitment of the Society to champion placenta as a stem cell source was realized with the inaugural meeting of IPLASS held in Brescia, Italy, in October 2010. Officially designated as an EMBO-endorsed scientific activity, international experts in the field gathered for a 3-day meeting, which commenced with “Meet with the experts” sessions, IPLASS member and board meetings, and welcome remarks by Dr. Ornella Parolini, President of IPLASS. The evening’s highlight was a keynote plenary lecture by Dr. Diana Bianchi. The subsequent scientific program consisted of morning and afternoon oral and poster presentations, followed by social events. Both provided many opportunities for intellectual exchange among the 120 multi-national participants. This allowed a methodical and deliberate evaluation of the status of placental cells in research in regenerative and reparative medicine. The meeting concluded with Dr. Parolini summarizing the meeting’s highlights. This further prepared the fertile ground on which to build the promising potential of placental cell research. The second IPLASS meeting will take place in September 2012 in Vienna, Austria. This meeting report summarizes the thought-provoking lectures delivered at the first meeting of IPLASS.

Published
2016

36. Toward Cell Therapy Using Placenta-Derived Cells: Disease Mechanisms, Cell Biology, Preclinical Studies, and Regulatory Aspects at the Round Table

Author

Cesar V. Borlongan, Giacomo Lanzoni, Stephen C. Strom, Maddalena Soncini, Ornella Parolini, Sankar Venkatachalam, Massimo Dominici, Steffen M. Zeisberger, Maria Luisa Nolli, Bing Liu, Peter De Waele, Daniel Surbek, Francesco Alviano, Diana Boraschi, Susanne Wolbank, Luca Romagnoli, Cosimo De Bari, Fabio Marongiu, David C. Hess, Andy Zeitlin, Stefan Mohr, Abraham Solomon, Werner Falk, Andreas H. Zisch, Marco Evangelista, Peter Ponsaerts, Colin McGuckin, Irene Bergwerf, Racheli Ofir, Simone Hennerbichler, University of Zurich, Parolini, O, Parolini O., Alviano F., Berwerf I., Boraschi D., De Bari C., De Waele P., Dominici M., Evangelista M., Falk W., Hennerbichler S., Hess D.C., Lanzoni G., Liu B., Marongiu F., McGuckin C., Mohr S., Nolli M.L., Ofir R., Ponsaerts P., Romagnoli L., Solomon A., Soncini M., Strom S., Surbek D., Venkatachalam S., Wolbank S., Zeisberger S., Zeitlin A., Zisch A., and Borlongan C.V.

Subjects
Cell type, HUMAN TERM PLACENTA, AMNIOTIC EPITHELIAL-CELLS, Placenta, 2720 Hematology, Cell- and Tissue-Based Therapy, 610 Medicine & health, Cell Separation, Biology, Regenerative medicine, 1309 Developmental Biology, 1307 Cell Biology, Cell therapy, Pregnancy, Settore BIO/13 - BIOLOGIA APPLICATA, Animals, Humans, Good manufacturing practice, Disease Models, Animal, Female, Inflammation, Stem Cells, Hematology, Developmental Biology, Cell Biology, 10026 Clinic for Obstetrics, Animal, Disease mechanisms, MESENCHYMAL STEM CELLS, Clinical reality, 10022 Division of Surgical Research, Round table, Risk analysis (engineering), Disease Models, Immunology, Human medicine, cell therapy, Stem cell
Abstract

Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results